Introduction
The majority of chemotherapeutic agents have been identified by their cytotoxic effects on panels of human tumor-derived cell lines. This approach has also revealed associations between cancer-specific mutations and drug sensitivity. Many studies have reported correlations between drug responsiveness and tumor genotypes. As the p53 gene is inactivated in the majority of human cancers (Hollstein et al., 1991) , much effort has therefore been spent to determine the effects of p53 inactivation on cancer cell response to therapeutic agents (Lowe et al., 1994; O'Connor et al., 1997) .
Functional analyses of p53 protein have revealed that it is a transcription factor with sequence-specific DNAbinding activity (Farmer et al., 1992; Kern et al., 1992; Zambetti et al., 1992) , and that it activates the transcription of several downstream target genes, including p21, an inhibitor of cyclin-dependent kinases (CDKs) (el-Deiry et al., 1993) . p21 induction causes subsequent arrest in the G1 phase by binding to cyclin E-and A-associated cdk2 complexes (Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993) . Recently, we reported that p53 and p21 also inactivate cyclin B-associated cdc2 kinase by repressing the transcription of cyclin B, cdc2, and cdc25C genes, and that this repression is mediated by the cdk2-dependent phosphorylation of NF-Y (Park et al., 2000; Yun et al., 2003; Chae et al., 2004) . Other recent studies have described additional p53 target genes that are likely to activate cell cycle checkpoints and induce apoptosis (Vousden and Lu, 2002) .
The loss of p53 function has been shown to determine cellular sensitivities to genotoxic agents (Lowe et al., 1993; Fan et al., 1994; McIlwrath et al., 1994) and mitotic spindle inhibitors (Trielli et al., 1996; Wahl et al., 1996; Debernardis et al., 1997; Fan et al., 1998) . p53 was also found to modulate the cytotoxicity of anticancer agents. Experiments comparing transformed fibroblasts of normal and p53-deficient mice demonstrated that disruption of p53 function reduces the apoptosis induced by anticancer agents (Lowe et al., 1993) . Subsequent in vivo studies provided further support for this notion (Lowe et al., 1994; O'Connor et al., 1997) , and thus, the inactivation of apoptotic response remains an attractive explanation for the poor responsiveness of p53 mutant tumors to these agents. Therefore, he identification of chemotherapeutic agents that activate p53-independent apoptosis is of fundamental importance for the development of treatments for p53-deficient tumors.
In this study, we report on novel cell-based screening system for identifying mitosis inhibitors. Through screening of natural compounds that inhibit the mitosis of activated oocytes, we identified 12 natural cytokinesis inhibitors. Among these, pectenotoxin-2 (PTX-2), which was first identified as a cytotoxic compound in marine sponges and later found to be an actin-depolymerizing agent (Draisci et al., 1996; Hori et al., 1999) , was found to be highly toxic to p53-deficient cells. This finding led us to investigate the effects of PTX-2 and other actin inhibitors in tumors lacking a normal p53 gene.
Results

Identification of mitosis inhibitors using ovulated oocytes
Most mammalian ovulated oocytes arrest in the metaphase of the second meiotic division unless artificially stimulated or fertilized (Choi et al., 1991; Masui, 1996) . Using these synchronized cells, we developed a novel cell-based screening system to identify mitosis inhibitors. Ovulated oocytes are activated by treatment with ethanol, and then progress into the anaphase and complete mitosis. Thus, we applied 1100 natural compounds to screen for the mitosis inhibitors after treatment with ethanol. While normally activated oocytes completed mitosis and moved into the two-cell stage at 24 h and the four-cell stage at 48 h after ethanol treatment (Figure 1 ), some compound-treated oocytes failed to complete mitotic division, and remained in the one-cell stage, but with two nuclei (Figure 1 ). By using this approach, we identified 12 natural compounds that inhibit cytokinesis.
PTX-2 exhibits enhanced cytotoxic effect on p53-deficient tumors
We applied the cytokinesis inhibitors to human tumor cell lines and examined their cytotoxic effects. During this assay, we found that PTX-2, one of the inhibitors identified by screening, exhibited more enhanced cytotoxicity to p53-deficient tumor cells than p53-positive cells (data not shown). Thus, to compare the cytotoxic effects of PTX-2 to p53-positive and -deficient tumors, we employed HCT116 and its derivatives with both copies of p53 deleted and another expressing a dominant-negative mutant form of p53 (p53 À/À and p53 281 , respectively). Whereas the viability of HCT116 cells was largely unaffected by PTX-2 treatment at the concentrations tested, the HCT116 derivatives, p53 À/À and p53
281
, showed heightened chemosensitivity to PTX-2 ( Figure 2a) .
We also examined the cytotoxic effects of other actin inhibitors (Figure 2b ). Psychosine causes filamentous actin to knot, whereas others, such as cytochalasin D (cyto D), latrunculin A, jasplakinolide, and swinholide A, are actin depolymerizers (Spector et al., 1999) . All of the actin inhibitors tested in the present study showed more enhanced cytotoxicity to the HCT116 derivatives, p53 À/À and p53
, than parental cells (Figure 2b ).
Loss of p53 sensitizes tumors to actin inhibitors
To test whether the status of p53 in tumor cells correlates with their chemosensitivities to PTX-2, we chose six independent human lung cancer cell lines ( Figure 2c ) and two well-known hepatocarcinoma cell lines (HepG2 and Hep3B), and investigated cell viabilities after PTX-2 treatment ( Figure 2c ). All of the tested cell lines without functional p53, such as HCT116 derivatives, Hep3B, and all the lung cancer cell lines except for A549, were much more sensitive to PTX-2 than p53-positive cells, such as HCT116, HepG2, and A549, although the degrees of sensitivity varied somewhat ( Figure 2c ). Applying these results therapeutically to tumors lacking p53, we compared the effects of PTX-2 on the tumor development of p53-positive and -negative tumor cells in nude mice (Figure 2d ). We subcutaneously injected nude mice with HCT116 or its p53-null derivative (p53
). After tumors grew to a mean size of 100 mm 3 (day 0), the mice were treated with a daily intraperitoneal injection of 0.1 mg/kg PTX-2 or its matching vehicle (PBS) for 20 days. PTX-2 did not affect tumor growth in the mice with HCT116 tumor cells, but the mean volume increase in tumors in those carrying p53-null cells receiving PTX-2 was reduced to 48% of that of the control group injected with PBS ( Figure 2d ). The body weights of mice were not significantly affected by PTX-2 (data not shown).
Actin damage triggers intrinsic death signals
After PTX-2 treatment, p53
À/À cells, but not parental HCT116 cells, showed various apoptosis-specific phenomena, such as DNA laddering and morphological changes (data not shown). Cellular damage transduces intrinsic death signals to mitochondria, resulting in the disruption of mitochondrial membrane potential ( m ) across the inner membrane, which in turn leads to the release of several proapoptotic molecules, including cytochrome c and Smac/Diablo, into the cytosol and to the activation of caspases (Vaux and Korsmeyer, 1999) . Staurosporine (STS), an agent that potently destabilizes the mitochondrial membrane potential and triggers apoptosis (Green and Reed, 1998) , was used as a control to determine the effects of actin inhibitors on the mitochondrial membrane potential. STS decreased Dc m before the appearance of apoptotic cells stained with propidium iodide (PI) regardless of p53, whereas actin inhibitors reduced Dc m in p53 À/À cells, but not in parental cells (Figure 3a) .
Consistent with mitochondrial dysfunction, cytoplasmic cytochrome c and Smac/DIABLO were increased in p53 À/À cells (Figure 3b ). Western blot analysis also showed that active forms of both caspase-9 and -3 were elevated in p53 À/À cells under these conditions, but not in parental cells (Figure 3b) . Consistently, the cleavage of poly(ADP-ribose) polymerase (PARP), a DNA repair protein that is cleaved by caspases during the execution phase of apoptotic cell death (Slee et al., 1999) , was observed in p53-deficient cells (Figure 3b ). An in vitro caspase activity also showed the significant activation of caspase-3 in p53 À/À cells (Figure 3c ). The caspasedependent induction of apoptosis was supported by the observation that cell death was significantly inhibited by pretreating cells with the caspase-3 inhibitor z-DEVD-FMK (Figure 3d) . Thus, apoptosis in cells treated with actin inhibitor is likely to be triggered by an intrinsic pathway, as was previously observed in DNA-damaged cells.
Apoptosis induced by PTX-2 is Bim/Bax-mediated
To identify the molecular mechanisms by which PTX-2 causes a loss of the mitochondrial membrane potential, we examined the protein levels of proapoptotic Bcl-2 family proteins. Owing to the absence of a change in the total protein level of Bax after PTX-2 treatment (Figure 4a) , we investigated the possibility of Bax conformational changes. Immunoprecipitation analysis using anti-Bax 6A7 antibody and recognizing only the conformationally changed Bax protein showed that active Bax was markedly elevated in p53-deficient cells, but not in parental cells (Figure 4a ). Of the BH3-only proteins that activate multidomain proapoptotic members such as Bax (Cheng et al., 2001) , we found that Bim was differentially regulated in p53 À/À and parental cells, whereas p53
À/À cells significantly induced Bim expression, parental cells did not (Figure 4a ).
To determine whether either or both of Bax and Bim are critical for apoptosis induced by PTX-2, we used the SiRNA-mediated gene silencing technique. Transfection with SiRNA for either Bax or Bim inhibited the cell death induced by PTX-2 (Figure 4b ). In addition, SiRNA for either Bax or Bim inhibited the activation of both caspase-3 and -9 (Figure 4c ). Although SiRNA for Bim did not affect Bax expression, we addressed the possibility that conformational changes of Bax are dependent on Bim. Figure 4d shows that SiRNA for Bim blocked the activation of Bax proteins by PTX-2 (Figure 4d ). These results imply that Bim is required for conformational activation of Bax after PTX-2 treatment.
Discussion
In this study, we demonstrate a novel cell-based screening system based on the use of mammalian ovulated oocytes to identify mitosis inhibitors (Figure 1 ). This system allowed us to screen for cytokinesis inhibitors, and, as a result, we found that PTX-2 is markedly toxic to p53-deficient tumors both in vitro and in vivo (Figure 2 ). Other agents that are known to cause actin damage via depolymerization or knotting of actin filament also showed enhanced cytotoxicity in p53-deficient tumor cell (Figure 2) , implying that the loss of p53 sensitizes tumors to actin damage. , psychosine (psycho, 50 mM), or STS (100 nM) for the times indicated. DC m was assessed by determining fluorescent dye (DiOC 6 ) uptake as described in 'Materials and methods'. (b) Cells were treated with PTX-2 (100 ng/ml) for the indicated times. Cytosolic fractions were then prepared and subjected to Western blot analysis (upper three panels). Whole cell extracts were prepared and assessed by Western blotting for PARP, cleaved caspase-3, cleaved caspase-9, and XIAP. (c) Enhancement of caspase-3 activity after the treatment with actin inhibitor. HCT116 p53 À/À cells were treated with the three different actin inhibitors (100 ng/ml PTX-2, 10 mM cyto D, or 50 mM psychosine) for 2 days or with STS (0.1 mM) for 12 h. Caspase-3 activity was determined as described in 'Materials and methods'. (d) Prevention of cell death by a caspase-3 inhibitor. p53
À/À cells were treated with PTX-2 (100 ng/ml) and a caspase-3 inhibitor (Z-DEVD-FMK, 25 mM) for 3 days. Cell viability was determined by trypan blue exclusion To examine why p53-deficient tumor cells are more chemosensitive, we analysed the cellular responses of p53 À/À and of its parental cells after actin damage. It is known that mitochondria integrate death signals through Bcl-2 family members and coordinate caspase activation through the release of cytochrome c and Smac/DIABLO as a result of a loss of membrane potential (Dc m ) and increased permeability through the outer membrane. We showed that this mitochondrial apoptosis pathway is involved in the apoptosis induced by actin damage. Thus, our results suggest that some Bcl-2 family proteins are differentially regulated in p53 À/À cells and parental cells.
The Bcl-2 family proteins consist of both anti-and proapoptotic members. They are critical death regulators that reside immediately upstream of mitochondria. Bax translocation to mitochondria is believed to play a key role in the induction of apoptosis by initiating the release of apoptotic factors such as Smac/DIABLO and cytochrome c when induced to do so by a variety of apoptotic stimuli (Gross et al., 1999) . Bax translocation involves a conformational change that exposes the NH 2 terminus and the hydrophobic COOH terminus that targets mitochondria (Nechushtan et al., 1999) . Bax conformation changes were induced by PTX-2 treatment (Figure 4a ), and this was further supported by immunostaining with anti-Bax antibody (data not shown). Thus, the conformational change and translocation of Bax are likely to initiate PTX-2-induced apoptosis.
BH3-only proteins, including Bim, require for the activation of multidomain proapoptotic proteins, such as Bax, to exert their mitochondrial proapoptotic activity (Scorrano and Korsmeyer, 2003) . Experiments with knockout mice have shown that Bim is essentially required for apoptosis (Bouillet et al., 1999) . We found that Bim expression was induced in p53-deficient cells by PTX-2 treatment. Furthermore, the knockdown of either Bax or Bim by SiRNA-mediated gene silencing abolished PTX-2-induced apoptosis (Figure 4 ). This knocking down of the expression of Bax and Bim by RNA interference demonstrates that Bim-mediated Bax activation is essential for apoptosis induction in p53 À/À cells after actin damage.
Although it is not clear which downstream effectors are involved in actin damage, and thus influence cell sensitivity to actin inhibitors, it can be speculated that the basis of the differential sensitivity occurs downstream of actin damage. Future studies will be directed to identify the regulator involved in the induction of Bim expression following actin damage, and also functions differentially according to the state of p53.
Materials and methods
Identification of chemical compounds that inhibit oocyte activation
The mice used in this study were ICR females, 3-4 weeks of age. To obtain ovulated oocytes, female mice were injected with 5 IU of pregnant mare's serum gonadotrophin (PMSG) and, 48 h later, with 5 IU of human chorionic gonadotrophin (hCG). Ovulated oocytes were collected from the ampulla of oviducts 14-16 h after the hCG injection. Cumulus-enclosed oocytes were isolated, and the cumulus cells were dispersed by incubation for 2-3 min in 0.1% hyaluronidase in culture medium (modified Whitten's medium containing 0.4% bovine serum albumin) at 38.51C in a humidified atmosphere of 5% CO 2 and 95% air.
The cumulus-free oocytes were activated by treatment with 7% ethanol in culture for 7 min at room temperature (RT). , which is a dominant-negative mutant form of p53, we transfected HCT116 with pCMV-p53 281 plasmid (Yun et al., 1999) . DNA transfections were performed using the CaPO 4 co-precipitation procedure (Graham and van der Eb, 1973) . HCT116 and its derivatives, human hepatocarcinoma cell lines (HepG2, Hep3B), and lung cancer cell lines (Calu-3, SK-LU-1) were maintained in DMEM supplemented with 10% FBS (Life Technologies, Inc., Grand Island, NY, USA) and penicillin-streptomycin (50 U/ ml). Other lung cancer cell lines (A549, HCC-2108, H358, H1299) were grown in RPMI1640 supplemented with 10% FBS and penicillin-streptomycin (50 U/ml). Unless otherwise indicated, drugs were added directly to cell media.
Gene silencing with small interfering RNAs
SiRNAs (sense and antisense strands) were purchased from Proligo (Paris, France). The sense strand sequences were as follows: Bim, 5 0 -CAAUUGUCUACCUUCUCGG(dTdT)-3 0 ; Control, 5 0 -UUCUCCGAACGUGUCACGU(dTdT)-3 0 ; and Bax, 5 0 -GGUGCCGGAACUGAUCAGA(dTdT)-3 0 (Bidere et al., 2003; Reginato et al., 2003) . Cells were transfected with SiRNAs by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instruction. At 24 h after transfection, the cells were treated with PTX-2 (100 ng/ ml) for 2 days, and then collected for either Western blot analysis, or trypan blue exclusion assay.
Cytotoxicity and apoptosis assays
Mitochondrial membrane potentials and viabilities were, respectively, assessed using 3,3 0 -dihexyloxacarbocyanine (DiOC 6 ) (Molecular Probes, Eugene, OR, USA) and (PI) as described previously (Valavanis et al., 2001) . Cells were seeded at 10 6 cells/100 mm dish 36 h before adding PTX-2 (100 ng/ml), cyto D (10 mM), psychosine (50 mM), or STS (0.1 mM). The cells were then incubated for the indicated times, trypsinized, washed, suspended in PBS, stained with DiOC 6 and PI, and analysed by flow cytometry (Coulter EPICS XL, Coulter Electronics, Hialeah, FL, USA). The activation of caspase-3 was detected using a Caspase-3 assay Kit (BD Pharmingen, San Diego, CA, USA), which uses N-acetyl-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC) as a substrate. Cell viability was determined by trypan blue exclusion using at least 300 cells in each group.
Western blot analyses
In all, 20 mg of protein was subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PolyScreen membranes (NEN, Boston, MA, USA). The membranes were then blocked with 5% nonfat dry milk in TBST buffer (Jung et al., 2001) and probed with antibodies. The following antibodies were used; antibodies against cytochrome c, poly(ADP-ribose) polymerase (PARP), and Smac/DIABLO (BD Pharmingen, San Diego, CA, USA); cleaved caspase-9, and cleaved capase-3 (Cell Signaling Technology, Beverly, MA, USA); actin, Bax, tubulin, and HSP60 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies were detected using a horseradish peroxidase-conjugated goat anti-mouse, goat anti-rabbit or donkey anti-goat secondary antibody by enhanced chemiluminescence (Amersham, Buckinghamshire, UK).
Subcellular fractionation
Cells were resuspended in an isotonic buffer (10 mM HEPES, pH 8.0, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mg/ml pepstatin A) and homogenized using a 26-gauge syringe needle. Cell homogenates were spun at 1000 g to separate out unbroken cells, nuclei, and heavy membranes. The supernatant was then spun again at 14 000 g for 30 min to yield the mitochondrial (pellet) and cytosolic (supernatant) fractions. The mitochondrial fraction was then washed once with extraction buffer, and finally resuspended in RIPA buffer for Western blot analysis.
Detection of Bax conformational change
The detection of conformationally changed Bax was described previously (Yamaguchi et al., 2003) . Briefly cells were lysed with Chaps lysis buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 1% Chaps) containing protease inhibitors. The cell lysates were then normalized for protein content and 200 mg of total protein was incubated with 1 mg of anti-Bax 6A7 monoclonal antibody (Upstate, Charlottesville, VA, USA) in 500 ml of Chaps lysis buffer for 6 h at 41C. Then, 25 ml of protein Aagarose was added into the reactions and incubated at 41C for an additional 2 h to precipitate conformationally changed Bax protein. After three washings in Chaps lysis buffer, the resulting immune complexes were subjected to SDS-PAGE immunoblot analysis with anti-Bax polyclonal antibody (Santa Cruz Biotechnology).
Nude mouse assay
To establish tumors in mice, 5 Â 10 6 cells suspended in 100 ml of phosphate-buffered saline were injected subcutaneously into the right flanks of female nude mice (Balb/c, Charles River Laboratory, Hino, Japan). After tumors had grown to a mean size of 100 mm 3 , the animals received a daily intraperitoneal injection of either of PTX-2 (0.1 mg/kg dissolved in 100 ml of PBS) or of the vehicle control (PBS) for 20 days. Tumor volume (V) was estimated from daily short-and long-axis data using the following formula: V ¼ 0.5 Â a 2 Â b, where a and b stand for the short and long axes, respectively (Tsujii et al., 1998) .
